Newsroom

Sorted by: Latest
-

Heritage Global Partners to Conduct Two Massive Online Auctions of Wren Manufacturing’s Pennsylvania Plants

SAN DIEGO--(BUSINESS WIRE)--Heritage Global Partners (“HGP”), a subsidiary of Heritage Global Inc. (NASDAQ: HGBL) and a worldwide leader in asset advisory and auction services, will conduct two online auctions of cabinet manufacturing, woodworking and stone fabrication equipment formerly used in Wren Manufacturing’s U.S. operations in Wilkes-Barre, Pennsylvania. The sales are being conducted by order of the U.S. Bankruptcy Court, Case No. 1:26-bk-10581, which features equipment used in the prod...
-

IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through...
-

KW and Rejig.AI Collaborate to Expand AI-Powered Marketing for Agents

AUSTIN, Texas--(BUSINESS WIRE)--Rejig.AI helps KW-affiliated agents scale their marketing and strengthen local visibility...
-

Rosen Law Firm Urges XTI Aerospace, Inc. (NASDAQ: XTIA) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of XTI Aerospace, Inc. (NASDAQ: XTIA) between April 15, 2026 and August 17, 2026. XTI Aerospace describes itself as an “aerospace and advanced technology company.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that XTI Aerospace, Inc. (NAS...
-

Teledyne Surpasses 1,000 Scientific Imaging Sensors in Space with the Launch of NASA's Nancy Grace Roman Space Telescope

CAMARILLO, Calif.--(BUSINESS WIRE)--Teledyne Space Imaging, a leading supplier of space-qualified imaging sensors, focal plane arrays, and integrated camera systems, celebrated a major milestone following the successful launch of NASA's Nancy Grace Roman Space Telescope, which lifted off on August 30 aboard a SpaceX Falcon Heavy rocket from Kennedy Space Center in Florida. With the launch of Roman, there are now more than 1,000 Teledyne scientific imaging sensors in space, including those aboar...
-

BeOne Medicines公布全新第三期生存資料，進一步證實含ZIIHERA方案在一線HER2陽性胃食管癌治療中的獲益

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布第三期HERIZON-GEA-01試驗第二次期中分析(IA2)的積極初步主要結果。該試驗旨在評估ZIIHERA® (zanidatamab)聯合化療（加用和不加用TEVIMBRA® (tislelizumab)）用於一線治療人類表皮生長因子受體2陽性(HER2+)局部晚期或轉移性胃食管腺癌(GEA)的療效。在IA2中，相較於trastuzumab聯合化療，ZIIHERA聯合化療在整體存活期(OS)方面展現出具有統計學顯著性和臨床意義的改善，達到了本研究剩餘的主要終點分析。 IA2同時為TEVIMBRA聯合ZIIHERA及化療方案提供了更長隨訪期的資料，顯示出改善的OS風險比、持續的療效以及整體可控的安全性特徵。這些結果進一步印證了IA1的發現——該方案達到了無惡化存活期(PFS)和OS終點，且在PD-L1和HER2陽性表達水準中均觀察到整體存活期獲益。 BeOne Medic...
-

Samenvatting: BeOne Medicines kondigt nieuwe overlevingsgegevens uit Fase 3-studie aan die het voordeel bevestigen van behandelregimes met ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag positieve hoofdresultaten bekendgemaakt van de tweede tussentijdse analyse (IA2) van de Fase 3-studie HERIZON-GEA-01. In deze studie wordt ZIIHERA® (zanidatamab) onderzocht in combinatie met chemotherapie, al dan niet aangevuld met TEVIMBRA® (tislelizumab), als eerstelijnsbehandeling voor HER2-positief, lokaal gevorderd of gemetastaseerd gastro-oesofa...
-

BeOne Medicines anuncia nuevos datos de supervivencia de fase 3 que refuerzan el beneficio de los esquemas con ZIIHERA como tratamiento de primera línea del cáncer gastroesofágico HER2+

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología, anunció hoy resultados positivos del segundo análisis interino (IA2) del ensayo de fase 3 HERIZON-GEA-01, que evalúa ZIIHERA® (zanidatamab), en combinación con quimioterapia, con y sin TEVIMBRA® (tislelizumab), como tratamiento de primera línea para pacientes con adenocarcinoma gastroesofágico (GEA) HER2+ localmente avanzado o metastásico. En el IA2, la combina...
-

BeOne Medicines gibt neue Überlebensdaten aus Phase-3-Studien bekannt, die den Nutzen von ZIIHERA-haltigen Therapien bei HER2-positivem gastroösophagealem Krebs in der Erstlinienbehandlung untermauern

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute positive Topline-Ergebnisse der zweiten Zwischenanalyse (IA2) der Phase-3-Studie HERIZON-GEA-01 bekannt, in der ZIIHERA® (Zanidatamab) in Kombination mit einer Chemotherapie, mit und ohne TEVIMBRA® (Tislelizumab), als Erstlinienbehandlung bei HER2-positivem lokal fortgeschrittenem oder metastasiertem gastroösophagealem Adenokarzinom (GEA) u...
-

BeOne Medicines annonce de nouvelles données de survie issues d'un essai de phase III qui confirment les bénéfices des schémas thérapeutiques à base de ZIIHERA dans le cadre du traitement de première intention du cancer gastro-œsophagien HER2+

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, a annoncé aujourd’hui les premiers résultats positifs de la deuxième analyse intermédiaire (IA2) de l’essai de phase III HERIZON-GEA-01 évaluant le ZIIHERA® (zanidatamab), en association avec une chimiothérapie, avec ou sans TEVIMBRA® en tant que traitement de première intention de l’adénocarcinome gastro-œsophagien (GEA) HER2+ localement a...